Published in Medical Letter on the CDC and FDA, January 13th, 2002
The NIH decision to pursue this clinical research is significant because prostatitis, while affecting 50% of all men during their lifetime, is not well understood or studied, leading to difficulty diagnosing and treating the condition. The NIH multisite, double-blind, placebo-controlled, randomized study is the first designed to evaluate the efficacy, safety, and tolerability of an alpha-blocker (Flomax, tamsulosin HCL) and an oral antibiotic...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.